Annovis Bio Inc. (NYSE: ANVS), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy buntanetap for Alzheimer's and Parkinson's diseases, announced that Founder, President and CEO Maria Maccecchini, Ph.D., will participate in two industry conferences in November. The appearances matter because they give the company a platform to detail its clinical progress and upcoming milestones to investors and potential partners at a pivotal time for its lead drug candidate.
At U.S. Biotech Day 2026, scheduled for Nov. 16-17 in Philadelphia, Maccecchini will join a panel discussion titled “Bridging the Translational Gap: From Discovery Insights to Clinical Proof” on Nov. 16 from 9:15-9:45 a.m. ET, followed by a company presentation from 10:15-10:30 a.m. ET highlighting Annovis’ clinical programs and upcoming milestones. The panel topic is particularly relevant for Annovis, whose buntanetap is designed to bridge the gap between discovery research and clinical proof by targeting the underlying causes of neurodegeneration.
Maccecchini will also present at Pharma Partnering Summit 2026, scheduled for Nov. 19-20 in Boston. Her presentation, titled “Restoring Proteostasis in Alzheimer’s and Parkinson’s Diseases with Buntanetap, a Translational Inhibitor of Neurotoxic Proteins,” will take place Nov. 19 from 11:25-11:55 a.m. ET. During both events, she will hold one-on-one meetings with biotechnology and pharmaceutical industry representatives to discuss the company’s clinical progress and potential opportunities. Such partnering discussions can be critical for a clinical-stage company seeking to advance its pipeline and secure resources for late-stage development.
Headquartered in Malvern, Pennsylvania, Annovis Bio is developing treatments for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD). The company’s lead drug candidate, buntanetap (formerly posiphen), is an investigational once-daily oral therapy that inhibits the translation of multiple neurotoxic proteins, including APP and amyloid beta, tau, alpha-synuclein, and TDP-43, through a specific RNA-targeting mechanism of action. By addressing the underlying causes of neurodegeneration, Annovis aims to halt disease progression and improve cognitive and motor functions in patients. For more information, visit www.annovisbio.com and follow the company on LinkedIn and X. The latest news and updates relating to ANVS are available in the company’s newsroom at https://ibn.fm/ANVS.
The conference schedule comes as Annovis continues to advance buntanetap in Phase 3 development, making the CEO’s presentations and one-on-one meetings a key opportunity to communicate the drug’s potential to a broader industry audience. For a company focused on neurodegenerative diseases with significant unmet need, visibility among biotechnology and pharmaceutical representatives can influence partnership discussions and investor perception. The full press release is available through https://ibn.fm/0D5yA.
MissionIR, which distributes the announcement, is a specialized communications platform focused on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 75+ brands within the Dynamic Brand Portfolio at IBN that delivers access to a vast network of wire solutions via InvestorWire and editorial syndication to 5,000+ outlets, among other services. For more information, visit MissionIR.
